In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development
Wendy Walwyn(University of California, Los Angeles), Jonathan Zalevsky(Nektar Therapeutics (United States)), Catherine M. Cahill(University of Southern California), Suchi Tiwari(University of California, Los Angeles), Kathryn DeFea(Temecula Valley Unified School District), Takahiro Miyazaki(Nektar Therapeutics (United States)), Isabel Bishop(University of California, Los Angeles), Laurie A. VanderVeen(Gilead Sciences (United States)), Nicole Romaneschi(University of California, Los Angeles), Vartan Matossian(University of California, Los Angeles)
Cited by 4
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403